Biohaven Pharmaceutical Holding Co Ltd (BHVN) VP Kimberly Gentile Sells 5,000 Shares

Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) VP Kimberly Gentile sold 5,000 shares of Biohaven Pharmaceutical Holding Co stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $29.28, for a total transaction of $146,400.00. Following the transaction, the vice president now directly owns 5,000 shares in the company, valued at $146,400. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Biohaven Pharmaceutical Holding Co Ltd (BHVN) traded up $0.08 during midday trading on Friday, hitting $29.44. The stock had a trading volume of 333,313 shares.

COPYRIGHT VIOLATION WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) VP Kimberly Gentile Sells 5,000 Shares” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/03/biohaven-pharmaceutical-holding-co-ltd-bhvn-vp-kimberly-gentile-sells-5000-shares.html.

BHVN has been the topic of a number of analyst reports. Morgan Stanley lifted their price objective on shares of Biohaven Pharmaceutical Holding Co from $28.00 to $47.00 and gave the stock an “overweight” rating in a report on Monday, September 25th. Zacks Investment Research raised shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Friday, September 8th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, September 12th. BidaskClub downgraded shares of Biohaven Pharmaceutical Holding Co from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price objective (up from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $40.80.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Deschutes Portfolio Strategy LLC bought a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth $374,000. Alps Advisors Inc. bought a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth $1,316,000. American Century Companies Inc. bought a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth $1,375,000. State of Wisconsin Investment Board bought a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth $262,000. Finally, Emerald Mutual Fund Advisers Trust bought a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth $7,483,000.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

What are top analysts saying about Biohaven Pharmaceutical Holding Co Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biohaven Pharmaceutical Holding Co Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit